Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	26.85	25.94	14.94	21.39	16.31	14.41
Cash & Short-Term Investments	26.85	25.94	14.94	21.39	16.31	14.41
Cash Growth	5.78%	73.69%	-30.17%	31.17%	13.18%	-32.35%
Receivables	24.89	11.76	5.36	3.41	1.85	5.47
Inventory	10.14	15.42	15.23	0.91	0.56	0.55
Prepaid Expenses	6.73	7.46	5.49	1.13	1.29	3.18
Total Current Assets	68.6	60.58	41.02	26.84	20	23.6
Property, Plant & Equipment	1.47	0.64	0.21	0.15	0.26	0.22
Other Intangible Assets	45.68	30.88	34.88	4.74	4.75	3.62
Other Long-Term Assets	0.06	0.02	0.01	0.01	0.01	0.02
Total Assets	115.81	92.11	76.12	31.74	25.03	27.47

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	14.41	10.98	4.17	1.85	1.77	1.77
Accrued Expenses	18.95	15.94	15.7	8.96	3.66	1.37
Current Portion of Long-Term Debt	8.83	8.79	-	5.38	1.03	1.42
Current Portion of Leases	0.24	0.07	0.08	0.05	-	-
Current Unearned Revenue	0.33	0.46	-	-	-	-
Other Current Liabilities	2.38	2.26	-	-	-	-
Total Current Liabilities	45.12	38.49	19.95	16.24	6.46	4.56
Long-Term Debt	19.08	21.77	29.81	-	5.38	5.26
Long-Term Leases	1.08	0.46	0.11	0.02	0.11	0.02
Long-Term Unearned Revenue	1.62	1.76	-	-	-	-
Other Long-Term Liabilities	2.32	3.48	1.83	-	-	-
Total Liabilities	69.22	65.96	51.7	16.26	11.95	9.84

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.03	0.03	0.03	0.03	0.03	0.03
Additional Paid-In Capital	145.92	138.62	132.29	119.52	116.19	111.72
Retained Earnings	-99.36	-112.49	-107.89	-104.07	-103.13	-94.11
Total Common Equity	46.59	26.15	24.43	15.48	13.08	17.63
Shareholders' Equity	46.59	26.15	24.43	15.48	13.08	17.63
Total Liabilities & Equity	115.81	92.11	76.12	31.74	25.03	27.47

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	29.23	31.08	29.99	5.46	6.52	6.7
Net Cash (Debt)	-2.38	-5.14	-15.06	15.93	9.78	7.71
Net Cash Growth	-	-	-	62.90%	26.85%	-45.52%
Net Cash Per Share	-0.08	-0.19	-0.58	0.62	0.39	0.31
Filing Date Shares Outstanding	28.58	27.28	26.82	25.69	25.46	24.63
Total Common Shares Outstanding	28.29	27.05	26.71	25.69	25.35	24.63
Working Capital	23.48	22.09	21.07	10.6	13.54	19.05
Book Value Per Share	1.65	0.97	0.91	0.60	0.52	0.72
Tangible Book Value	0.91	-4.72	-10.45	10.74	8.32	14.01
Tangible Book Value Per Share	0.03	-0.17	-0.39	0.42	0.33	0.57
Machinery	0.24	0.52	0.38	0.35	0.34	0.4
Construction In Progress	-	-	-	-	0.01	-
Leasehold Improvements	0.23	0.3	0.1	0.1	0.07	0.07

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 7, 2026

Data Sources Report a data error